Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Teva Reports Second Quarter 2018 Financial Results
August 2, 2018 7:00 AM EDTRevenues of $4.7 billion Free cash flow of $0.6 billion GAAP diluted loss per share of $0.24 Non-GAAP diluted EPS of $0.78 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and in total $3.0 billion by the end of 2019 Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.55-2.80 from $2.40-$2.65 Free cash flow guidance raised to $3.2-3.4 billion from $3.0-3.2 billion
JERUSALEM--(BUSINESS WIRE)--... More
